ADIA Nutrition Inc. Requests SIC Code Update to 2836 (Biological Products) with SEC and OTC Markets
ADIA Nutrition (OTCQB: ADIA) filed with the SEC and OTC Markets on November 17, 2025 to update its Standard Industrial Classification to 2836 (Biological Products, Except Diagnostic), replacing prior codes 2834 and 6719 to better reflect its biologics manufacturing and clinic operations.
The company noted Adia Labs sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) nationwide and Adia Med clinics provide regenerative treatments. The change will take effect on ADIA's next filings. ADIA also highlighted 200%+ Q3 2025 revenue growth, OTCQB uplisting progress, and an expanding clinic network.
ADIA Nutrition (OTCQB: ADIA) ha presentato con la SEC e OTC Markets il 17 novembre 2025 per aggiornare la sua Standard Industrial Classification a 2836 (Prodotti biologici, esclusi diagnostici), sostituendo i codici precedenti 2834 e 6719 per riflettere meglio le sue attività di produzione di biologici e operazioni cliniche.
L'azienda ha osservato che Adia Labs vende 361 HCT/P registrati dalla FDA (AdiaVita, AdiaLink) a livello nazionale e che le cliniche Adia Med offrono trattamenti rigenerativi. Il cambiamento entrerà in vigore con i prossimi filing di ADIA. ADIA ha anche evidenziato una crescita dei ricavi nel terzo trimestre 2025 superiore al 200%, i progressi verso l'inclusione nell'OTCQB e l'espansione della rete di cliniche.
ADIA Nutrition (OTCQB: ADIA) presentó ante la SEC y OTC Markets el 17 de noviembre de 2025 para actualizar su Clasificación Industrial Estándar a 2836 (Productos biológicos, excepto diagnósticos), reemplazando los códigos anteriores 2834 y 6719 para reflejar mejor sus operaciones de fabricación de biológicos y clínicas.
La empresa señaló que Adia Labs vende 361 HCT/P registrados por la FDA (AdiaVita, AdiaLink) a nivel nacional y que las clínicas Adia Med proporcionan tratamientos regenerativos. El cambio entrará en vigor en las próximas presentaciones de ADIA. ADIA también destacó un crecimiento de ingresos de >200% en el tercer trimestre de 2025, el progreso hacia un listado en OTCQB y una red de clínicas en expansión.
ADIA Nutrition (OTCQB: ADIA)가 2025년 11월 17일 SEC 및 OTC Markets에 제출하여 표준산업분류를 2836 (생물학적 제품, 진단 제외)로 업데이트하고 이전 코드 2834 및 6719를 대체하여 생물학 제제 제조 및 임상 운영을 더 잘 반영했습니다.
회사에 따르면 Adia Labs는 FDA에 등록된 361 HCT/Ps(AdiaVita, AdiaLink)를 전국적으로 판매하고 Adia Med 클리닉이 재생 치료를 제공한다고 합니다. 이 변경은 ADIA의 다음 제출에서 발효됩니다. 또한 ADIA는 2025년 3분기 매출이 200% 이상 증가했다고 강조했고, OTCQB 상장 진행 및 확장 중인 임상 네트워크를 언급했습니다.
ADIA Nutrition (OTCQB : ADIA) a déposé auprès de la SEC et des marchés OTC le 17 novembre 2025 afin de mettre à jour sa Classification Industrielle Standard à 2836 (Produits biologiques, sauf diagnostics), remplaçant les codes précédents 2834 et 6719 pour mieux refléter ses activités de fabrication de biologiques et ses opérations cliniques.
L'entreprise a noté que Adia Labs vend des 361 HCT/P enregistrés par la FDA (AdiaVita, AdiaLink) à l'échelle nationale et que les cliniques Adia Med fournissent des traitements régénératifs. Le changement entrera en vigueur lors des prochaines dépôts d'ADIA. ADIA a également souligné une croissance des revenus de plus de 200 % au T3 2025, des progrès vers une cotation OTCQB et l'expansion du réseau de cliniques.
ADIA Nutrition (OTCQB: ADIA) hat am 17. November 2025 bei der SEC und OTC Markets eingereicht, um seine Standard Industrial Classification auf 2836 (Biologische Produkte, außer diagnostisch) umzustellen und damit die bisherigen Codes 2834 und 6719 zu ersetzen, um seine Biologika-Herstellung und klinischen Betriebe besser abzubilden.
Das Unternehmen wies darauf hin, dass Adia Labs bundesweit 361 HCT/Ps registriert bei der FDA verkauft (AdiaVita, AdiaLink) und Adia Med-Kliniken regenerative Behandlungen anbieten. Die Änderung tritt bei ADIA in Kraft bei den nächsten Einreichungen. ADIA hob außerdem ein Umsatzwachstum von über 200 % im Q3 2025, Fortschritte bei der OTCQB-Notierung und ein expandierendes Kliniknetzwerk hervor.
ADIA Nutrition (OTCQB: ADIA) قدمت إلى هيئة الأوراق المالية SEC وOTC Markets في 17 نوفمبر 2025 لتحديث التصنيف الصناعي القياسي إلى 2836 (المنتجات البيولوجية، باستثناء التشخيص)، مع استبدال الرمزين السابقين 2834 و6719 لتعكس بشكل أفضل عمليات التصنيع الحيوي والعيادات لديها.
أشارت الشركة إلى أن Adia Labs تبيع 361 HCT/Ps معتمدة من FDA على مستوى البلاد (AdiaVita, AdiaLink) وأن عيادات Adia Med توفر علاجات تجديدية. سيصبح هذا التغيير ساري المفعول في الملفات القادمة لـ ADIA. كما سلطت ADIA الضوء على نمو في الإيرادات يزيد عن 200% في الربع الثالث من 2025، وتقدم في الإدراج في OTCQB وتوسع شبكة العيادات.
- Filed SIC update to 2836 with SEC and OTC Markets
- Q3 2025 revenue growth of 200%+
- Nationwide sales of FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink)
- OTCQB uplisting progress underway
- Expanding clinic network supporting commercial scale
- None.
Winter Park, Florida--(Newsfile Corp. - November 17, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced it has filed with the SEC to update its Standard Industrial Classification (SIC) code from 2834 (Pharmaceutical Preparations) to 2836 (Biological Products, Except Diagnostic) and with OTC Markets to update from 6719 (Holding Companies, N.E.C.) to 2836 (Biological Products, Except Diagnostic), accurately reflecting its core business of manufacturing and distributing proprietary biologics.
Email to SEC
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/274544_sic_filing_corrections.jpg
This dual request aligns ADIA's classification with its real operations:
- Adia Labs LLC sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) sold nationwide to physicians.
- Adia Med clinics, owned by ADIA, perform specialty regenerative treatments including stem cell therapy, PRP, and advanced biologics.
"We are not a supplement, pharma, or holding company," said Larry Powalisz, CEO of ADIA Nutrition. "We are a biotech company scaling biological products through labs and clinics. Updating to SIC 2836 across both SEC and OTC Markets gives investors and partners full clarity on our true growth model."
The updates will take effect upon ADIA's next filings. ADIA's 2025 momentum,
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274544
FAQ
What change did ADIA (OTCQB: ADIA) file with the SEC on November 17, 2025?
When will ADIA's SIC code update to 2836 take effect for ADIA (OTCQB: ADIA)?
What revenue metric did ADIA report in the November 17, 2025 announcement?
How does the SIC 2836 change affect ADIA's business classification for investors?
What products and services justify ADIA's SIC code 2836 change (ADIA ticker)?
